IDiyas

For the Inventor, By the Inventor

Boston, MA, United States of America

Meredeth Ann McGowan

USPTO Granted Patents = 16

 

Average Co-Inventor Count = 10.1

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:

goldMedal16 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents
silverMedal2 out of 10 
 
Iomet Pharma Ltd.
 patents
where one patent can have more than one assignee

Years Active: 2017-2022

Loading Chart...
Loading Chart...
16 patents (USPTO):
1. 11319295 - Substituted phenyloxetane and phenyltetrahydrofuran compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2022-05-03),
2. 11319283 - Substituted cyclobutylbenzene compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2022-05-03),
3. 11230547 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2022-01-25),
4. 11208407 - Substituted phenyl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2021-12-28),
5. 11179389 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2021-11-23),
6. 11111232 - Substituted cyclobutylpyridine and cyclobutylpyrimidine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2021-09-07),
7. 11103493 - Substituted pyridinyl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2021-08-31),
8. 11096930 - Substituted imidazopyridine compounds as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan-2,3-dioxygenase (2021-08-24),
9. 10995085 - Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2021-05-04),
10. 10647705 - Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2020-05-12),
11. 10538497 - Compounds as indoleamine 2,3-dioxygenase inhibitors (2020-01-21),
12. 10501458 - Substituted bicyclic fused ring compounds as indoleamine-2,3-dioxygenase inhibitors (2019-12-10),
13. 10221178 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2019-03-05),
14. 10100064 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2018-10-16),
15. 9938281 - Purine inhibitors of human phosphatidylinositol 3-kinase delta (2018-04-10),

Title: Meredeth Ann McGowan: Innovator in IDO Inhibitors

Introduction

Meredeth Ann McGowan is a prominent inventor based in Boston, MA, known for her significant contributions to the field of pharmaceuticals. With a total of 16 patents to her name, she has made remarkable strides in developing compounds that target indoleamine 2,3-dioxygenase (IDO) inhibitors. Her work has the potential to impact the treatment and prevention of various IDO-associated diseases and disorders.

Latest Patents

Among her latest patents, McGowan has developed substituted cyclobutylbenzene compounds as IDO inhibitors. These compounds, along with their pharmaceutically acceptable salts, are disclosed for their potential uses in treating or preventing IDO-associated diseases. Additionally, she has introduced substituted phenyloxetane and phenyltetrahydrofuran compounds, which also serve as IDO inhibitors, highlighting her innovative approach to pharmaceutical development.

Career Highlights

Throughout her career, McGowan has worked with notable companies such as Merck Sharp & Dohme Corporation and Iomet Pharma Ltd. Her experience in these organizations has allowed her to refine her expertise in drug development and innovation.

Collaborations

McGowan has collaborated with esteemed colleagues, including Hua Zhou and Yongxin Han, further enhancing her research and development efforts in the pharmaceutical industry.

Conclusion

Meredeth Ann McGowan's contributions to the field of IDO inhibitors exemplify her dedication to innovation in pharmaceuticals. Her extensive patent portfolio and collaborative efforts underscore her role as a leading inventor in this critical area of research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…